
Here we give the stock returns of the constituents in both our Canadian Cannabis LPs Portfolio (designated with a *) and the American Cannabis MSOs Portfolio in May, in descending order, and this week, the Adj. EBITDA as a % of Net Revenue for each constituents - the higher the better - which is very helpful in determining the value of a company as compared to its peers and their latest quarterly financial reports (links provided):
- Cronos* (CRON): down 11.9% in May (down 1.9% this week)
- Adj. EBITDA of (42.2)% of Net Revenue
- Cronos Q1 Financial Metrics Show Improvement
- OrganiGram* (OGI): down 19.7% in May (down 6.0% this week)
- Adj. EBITDA of (0.3)% of Net Revenue
- Organigram Q2 Financial Metrics Mixed
- Green Thumb (GTBIF): down 25.7% in May (up 1.0% this week)
- Adj. EBITDA of 35.7% of Net Revenue
- Net Profit of: 11.3% of Net Revenue
- Green Thumb Q1 Financial Metrics Excel Across The Board
- Curaleaf (CURLF): down 26.3% in May (down 1.3% this week)
- Adj. EBITDA of 22.6% of Net Revenue
- Curaleaf Reports 16% Reduction In Net Loss In Q1
- Cresco Labs (CRLBF): down 26.3% in May (down 1.0% this week)
- Adj. EBITDA of 28.8% of Net Revenue
- All Cresco Labs' QI Financial Metrics Down Except SG&A
- Tilray* (TLRY): down 27.1% in May (down 2.7% this week)
- Adj. EBITDA of 3.4% of Net Revenue
- Tilray's Q3 Financials Disappoint
- TerrAscend (TSNDF): down 29.4% in May (down 2.5% this week)
- Adj. EBITDA of 20.1% of Net Revenue
- TerrAscend Reports 64% Reduction In Net Loss In Q1 Financial Report
- Trulieve Cannabis (TCNNF): down 31.9% in May (down 6.1% this week)
- Adj. EBITDA of 35.5% of Net Revenue
- Trulieve Cannabis Q1 Financial Results Impressive
- Aurora Cannabis* (ACB): down 32.9% in May (down 7.1% this week)
- Adj. EBITDA of 3.4% of Net Revenue
- Aurora Cannabis Q3 Financials Unimpressive
- Verano (VRNOF): down 34.4% in May (up 1.2% this week)
- Adj. EBITDA of 30.3% of Net Revenue
- Verano Q1 Financial Metrics Down Across The BoardAyr Wellness (AYRWF): down 34.9% in May (down 2.6% this week)
- Adj. EBITDA of 24.7% of Net Revenue
- AYR Wellness' Q1 Financials Reveal 94% Reduction In Net Loss
- Canopy Growth* (CGC): down 42.0% in May (down 6.0% this week)
- Adj. EBITDA of (20.7)% of Net Revenue
- Cannabis Growth Q4 Financials Unimpressive
Summary
The above 12 stocks are down 3.3%, on average, this week and are down 31.2%, on average, since the beginning of May but are up 24.0% YTD.
More By This Author:
Cannabis Growth Q4 Financials Unimpressive
What Is Adjusted EBITDA? Here's How The Largest Cannabis Companies Compare
These 17 AI Stocks Are The Sector's Most Undervalued


.webp)
Comments
Log in or sign up to join the conversation.